PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed Pharmaceutical cure (OTCQB: CURR) (& # 39; the Company & # 39; & # 39;), a vertically integrated drug development and implementation company, committed to improving patient efficacy, safety, and experience through its patented dosage forms and administration systems. CEO Rob Davidson joined Stock Day host Everett Jolly.
To begin the interview, Davidson provided background information about the Company, as well as its future objectives. He explained that during the last year and a half, the Company has achieved some important milestones, among them, positioning itself with the DE, having recently received and expanded its manufacturing license record from List 1.
Then, Jolly asked if there are numerous biotechnology companies involved with cannabinoid pharmaceuticals. Davidson explained that previously, this was an area that was ignored, however, recently more and more companies are getting involved. Davidson also explained that dose regulations within the cannabis industry are still in development. However, he affirmed that the government and the FDA are analyzing solutions to this problem with care and strive to grant licenses only to companies that do not meet the highest standards.
Jolly asked about the Company’s recent press release regarding the acquisition of Chemistry Holdings, Inc. and what this means for the Company to move forward. Davidson shared that the acquisition represents a huge growth potential. “We are always looking to create a more expansive IP portfolio,” Davidson said. Acquisitions such as Chemistry Holdings, Inc. allow the company to increase its available technology, which can greatly improve its capabilities and value.
Jolly then asked about the company’s challenges in the last year. Davidson shared that one of the main challenges faced by the Company in 2018 was obtaining a manufacturing license from the DEA. However, this obstacle has been overcome. In the future, one of the main challenges that the Company will probably continue to face is the navigation of regulatory changes in the cannabis industry. The company relies on its ability to do so by following the required FDA and DEA guidelines as the industry becomes more defined.
Davidson then looked towards 2019 and shared his enthusiasm for the potential of the Company. He explained that the insured license with the DEA allows the Company to expand exponentially throughout 2019. & # 39; & # 39; We are one of the only drug distribution companies that have a manufacturing license from DEA List 1, “Davidson said. “We have seen the arrival of a large number of associations at the end of 2018 and 2019,” he added.
To close the interview, Davidson shared that the company has uniquely positioned itself to become a leader in this fast-growing industry. He added that the company’s intellectual property portfolio is extensive and represents significant value. “I think we’re on the ground floor of something really big and I think our investors have a great opportunity.”
To listen to the complete interview of Rob Davidson, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-robert-davidson-of-cure-pharmaceutical-holding-corp-otcqb-curr-2/
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company that is committed to improving patient efficacy, safety and expertise through its patented medication dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneer developer and manufacturer of a patented and proprietary delivery system (CUREfilm ™), one of the most advanced oral thin films on the market today. CURE is developing a range of products in innovative distribution platforms and partners with biotechnology and pharmaceutical companies. CURE has positioned itself to advance in numerous therapeutic categories, including the pharmaceutical cannabis sector with associations in the US. United States, Canada and Israel. The company’s mission is to improve people’s lives by redefining how medications are delivered and experienced.
For more information about CURE Pharmaceutical, visit its website at www.curepharma.com.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty of predicting the timing or result of research and development efforts of other products, the possible characteristics and indications of the products, marketing approvals and launches of other products, the impact of the pharmaceutical industry, the impact of products and competitive prices, the acceptance and demand of new pharmaceutical products, the impact of patents and other property rights of competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the judgment of the Company as of the date of this press release. The Company denies any attempt or obligation to update these forward-looking statements. This press release will not constitute an offer to sell or the solicitation of a purchase offer, nor will there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification as provided by law. securities laws of any state or jurisdiction.
About Uptick Newswire and the podcast & # 39; & # 39; Stock Day & # 39; & # 39;
Founded in 2013, Uptick Newswire is the fastest growing media store for the Nano-Cap and Micro-Cap companies. Educates investors while simultaneously working with penny stock and over-the-counter companies, providing transparency and clarification of the undervalued and under-sold Micro-Cap shares of the market. Uptick provides companies with customized solutions for news distribution in national and international media. Uptick is the sole producer of its “Stock Day” podcast, which is the number one radio program of its kind in the United States. The podcast of Uptick Network & # 39; & # 39; Stock Day is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE: Uptick Newswire